- Home
- A-Z Publications
- Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents)
- Previous Issues
- Volume 9, Issue 7, 2009
Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents) - Volume 9, Issue 7, 2009
Volume 9, Issue 7, 2009
-
-
Editorial [Hot Topic: Enzymes as Useful Tools and Potential Targets in Cancer Chemotherapy (Guest Editor: P. Ruzza and L. Quintieri)]
Authors: P. Ruzza and L. QuintieriCancer is the second leading cause of death in developed societies, and epidemiologists predict that in a few years it will overcome cardiovascular diseases to become the leading cause of mortality. Although the death rate of many forms of cancer seems to decrease, nevertheless most human tumours remain essentially incurable once they have spread, even though the chemotherapy era has been starting over 50 years ago. L Read More
-
-
-
Tyrosinase Activated Melanoma Prodrugs
Authors: Samaila Jawaid, Tariq H. Khan, Helen M.I. Osborn and Nana Aba O. WilliamsMetastatic malignant melanoma remains a highly aggressive form of skin cancer for which no reliable methods for treatment exist. Given the increasing incidence of this cancer, considerable attention has focused on the development of new and improved methods for tackling this disease. Within this article, methods for treating melanoma are reviewed and discussed with particular attention focusing on prodrugs that are a Read More
-
-
-
Proteases as Anti-Cancer Targets - Molecular and Biological Basis for Development of Inhibitor-Like Drugs Against Cancer
Authors: A. Bialas and P. KafarskiThe systematic improvement of methods used for unraveling physiological and pathological role of proteases, as well as for elucidation of relevant hydrolase structures contributes to the progress in the area of new inhibitor-like drugs development. Many of protease inhibitors have entered clinics and are now successfully applied for the treatment of various systemic disorders caused by deregulation of physiological process Read More
-
-
-
Glutathione Transferases as Targets for Cancer Therapy
Authors: Paolo Ruzza, Antonio Rosato, Carlo R. Rossi, Maura Floreani and Luigi QuintieriBesides catalyzing the inactivation of various electrophile-producing anticancer agents via conjugation to the tripeptide glutathione, some cytosolic proteins belonging to the glutathione transferase (formerly glutatione-S-transferase; GST) superfamily are emerging as negative modulators of stress/drug-induced cell apoptosis through the interaction with specific signaling kinases. In addition, several data link the overexpressio Read More
-
-
-
ATP Non-Competitive Ser/Thr Kinase Inhibitors as Potential Anticancer Agents
Authors: Giorgio Cozza, Andrea Bortolato, Ernesto Menta, Ennio Cavalletti, Silvano Spinelli and Stefano MoroProtein kinases are one of the largest known families of enzyme characterized by having a well conserved ATP binding pocket. Most of the synthetic kinase inhibitors are ATP-competitive, but display some potential problems, like selectivity, discrepancy between the in vitro and in vivo inhibition assays and an high risk of developing mutation inside the ATP-binding pocket. Recently some new inhibitors with a non-competitive mec Read More
-
-
-
WT1 Peptide Vaccine as a Paradigm for “Cancer Antigen-Derived Peptide”-Based Immunotherapy for Malignancies: Successful Induction of Anti-Cancer Effect by Vaccination with a Single Kind of WT1 Peptide
Wilms' tumor gene (WT1) possesses oncogenic functions and is expressed in various kinds of malignancies, which suggests that the gene's product, the WT1 protein, should be one of the most promising cancer antigens. In fact, the WT1 protein was shown to be highly immunogenic in cancer patients. WT1 peptides that could induce WT1-specific CTLs (WT1 CTL peptides) were identified, and vaccination of cancer patients with Read More
-
-
-
The Nitric Oxide Prodrug JS-K and Its Structural Analogues as Cancer Therapeutic Agents
Authors: Anna E. Maciag, Joseph E. Saavedra and Harinath ChakrapaniNitric oxide (NO) prodrugs of the diazeniumdiolate class are routinely used as reliable sources of nitric oxide in chemical and biological laboratory settings. O2-(2,4-dinitrophenyl) diazeniumdiolates, which are derivatized forms of ionic diazeniumdiolates, have been found to show potent anti-proliferative activity in a variety of cancer cells, presumably through the effects of NO. One important member of this class of diazenium Read More
-
-
-
Acronycine Derivatives: A Promising Series of Anti-Cancer Agents
Authors: Q. C. Nguyen, T. T. Nguyen, R. Yougnia, T. Gaslonde, H. Dufat, S. Michel and F. TillequinThe pyranoacridone acronycine (1) exhibits antitumor properties against a large panel of solid tumor models, but its moderate potency and low water solubility severely hampered the subsequent clinical trials. Development of synthetic analogues followed the isolation from several Sarcomelicope species of acronycine epoxide (17), which led to a hypothesis of bioactivation of acronycine by transformation of the 1,2- Read More
-
-
-
Targeting the Tumor Stroma with Peroxisome Proliferator Activated Receptor (PPAR) Agonists
Authors: Annika Bundscherer, Albrecht Reichle, Christian Hafner, Stefanie Meyer and Thomas VogtTumor cells depend on and are able to modulate the tumor stroma establishing a permissive and supportive environment of their own. Targeting the tumor stroma has evolved as a novel concept that has attracted attention of cancer researchers aiming at the treatment of metastatic cancer. The novel paradigm is that modulating the stroma will possibly not cure the cancer, but will make it a manageable disease for long perio Read More
-
Volumes & issues
-
Volume 25 (2025)
-
Volume 24 (2024)
-
Volume 23 (2023)
-
Volume 22 (2022)
-
Volume 21 (2021)
-
Volume 20 (2020)
-
Volume 19 (2019)
-
Volume 18 (2018)
-
Volume 17 (2017)
-
Volume 16 (2016)
-
Volume 15 (2015)
-
Volume 14 (2014)
-
Volume 13 (2013)
-
Volume 12 (2012)
-
Volume 11 (2011)
-
Volume 10 (2010)
-
Volume 9 (2009)
-
Volume 8 (2008)
-
Volume 7 (2007)
-
Volume 6 (2006)
Most Read This Month
Article
content/journals/acamc
Journal
10
5
false
en
